CompletedPhase 2

Pegasys® in Patients With Myeloproliferative Diseases

United States83 participantsStarted 2005-04-07

Plain-language summary

The goal of this clinical research study is to see if Pegasys (IFN-alpha2a) can help to control the disease in patients with ET, PV, AMM/MF, and Ph-negative CML. The safety of this treatment will also be studied.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Following diagnoses: --ET: Patients with PLT \> 600 x10 9 /l documented in the past 12 months; hyperplasia of marrow megakaryocytes in the absence of identifiable cause of thrombocytosis and in the absence of Ph chromosome. Patients with ET and lower PLT will be eligible if attributable to prior ET therapy. --PV: Patients should have Hb \>/= 15g/dl (except if patient is having phlebotomies done) and documented past diagnosis.
✓. Performance status \</= 2 (ECOG scale).
✓. Age greater than 18 years since disease is extremely rare in younger age group.
✓. Adequate liver function: total bilirubin of \</= 2.0 mg/dl (except for patients with Gilbert's Syndrome) and AST (SGOT) or ALT (SGPT) \< 3 X ULN (or \< 5 X ULN if considered due to tumor), and renal function (serum creatinine \</= 2.0 mg/dl).
✓. Signed informed consent indicating that patients are aware of the investigational nature of this study in keeping with the policies of the M.D. Anderson Cancer Center. The only acceptable consent form is the one approved by the M.D. Anderson Cancer Center IRB.
✓. Willingness and ability to comply with the requirements of the protocol for the duration of the study.
✓. Patients must have been off chemotherapy for 1 week prior to beginning Pegasys and have recovered from the toxic effects of that therapy. Patients may have received hydroxyurea or anagrelide immediately before study entry, and may continue into therapy if treating physician determines this is in the best interest of the patient.

Exclusion criteria

✕. Pregnant or lactating women.
✕. Patients with prior history of another malignancy or concurrent malignancy, except for the following: basal cell carcinoma of the skin, carcinoma in situ of the cervix, or other malignancies if the patient is disease free \>3 years.
✕. Patients with history of ischemic retinopathy.
✕. Patients with history of severe cardiac disease: NYHA Functional Class III or IV, myocardial infarction within 6 months, uncontrolled ventricular tachyarrhythmias or unstable angina.
✕. Patients with history of medically significant psychiatric disease if not controlled, especially endogenous depression (does not include reactive depression post-cancer diagnosis), psychosis and bipolar disease.
✕. Patients with seizure disorders requiring anticonvulsant therapy.
✕. Patients with known infection with HBV, HIV, or other active systemic infection.
✕. Patients with known autoimmune disease except for rheumatoid arthritis.

What they're measuring

Number of Patients With Complete Response (CR) or Partial Response (PR)

Timeframe: Up to 18 years

Trial details

NCT IDNCT00452023

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-26

Results submitted2024-04-17

View on ClinicalTrials.gov More Myeloproliferative Disorders trials